Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Outsourcing stability testing to full-service providers can offer comprehensive benefits to bio/pharma companies.


The Benefits of Outsourcing Stability Testing

The huge potential of biopharma is presenting an important epoch for outsourcing partners that can support the development and manufacture of biologics in an efficient way.


By Popular Demand: The Growth of Biopharma Outsourcing

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Can investing in early formulation studies drive a new therapy successfully across the commercialization finish line?

Fast vs. Formulated?

Eurofins DiscoverX partners with VelaLabs to enable VelaLabs to perform highly reproducible potency lot release assays under GLP/GMP conditions.

Eurofins DiscoverX Grants Bioassay Certification to VelaLabs

Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform.

ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement

Inhalation drug delivery company Vectura announces new organizational structure to drive innovation, customer focus, and growth.

Vectura Appoints Sharon Johnson Executive VP

Agnes Shanley is senior editor of Pharmaceutical Technology.

Quick approval pathways challenge teams to balance compliance with the need for speed. 

Pre-Clinical: Laying the Right Foundation

Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech. 

Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost. 

Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization

Catalent builds on its investment in cell and gene therapy development and manufacturing with the acquisition of MaSTherCell Global.

Catalent to Acquire MaSTherCell Global for $315 Million

In replacing the retiring Paul Hegwood, Ricci Whitlow will oversee global clinical trial operations.